Filters

Clear all

Expert Opinion

Plain Language Summary

Expert Review

Text Availability

Abstract

163

Full text

156

Free full text

Publication Types

Journal Article

160

Research Support, Non-U.S. Gov't

Randomized Controlled Trial

Clinical Trial, Phase I

Clinical Trial

Review

Comparative Study

Multicenter Study

Research Support, N.I.H., Extramural

Controlled Clinical Trial

Observational Study

Research Support, U.S. Gov't, Non-P.H.S.

Meta-Analysis

Clinical Trial, Phase II

Systematic Review

Letter

Validation Study

Case Reports

Research Support, U.S. Gov't, P.H.S.

Publication Year

From

Quick links

Individual year

2026

2025

2023

2022

2021

2020

2019

2018

2017

2016

2015

2014

2013

2012

2011

2010

2009

2008

2007

2006

Sort by:

selected

Print page

Email selected articles

Favourite selected articles

Create a NED Search Alert for this search

Save this search

Advanced Search

Run an advanced search

Results for
""Cytochrome P-450 CYP3A Inhibitors""[mesh_terms]

163 Results

Searching titles within these results

The role of ketoconazole in current prostate cancer care.

Vaibhav Patel, Bobby Liaw, William Oh

Nature reviews. Urology 2019;15(10):643-651

Full Text

Abstract

The Mechanism-Based Inactivation of CYP3A4 by Ritonavir: What Mechanism?

Nancy H C Loos, Jos H Beijnen, Alfred H Schinkel

International journal of molecular sciences 2022;23(17):9866

Free Full Text

Abstract

Versatile applicability of a grid-based CYP3A4 Template to understand the interacting mechanisms with the small-size ligands; part 3 of CYP3A4 Template study.

Yasushi Yamazoe, Takahiro Goto, Masahiro Tohkin

Drug metabolism and pharmacokinetics 2020;35(3):253-265

Full Text

Abstract

Enzyme- and transporter-mediated beverage-drug interactions: An update on fruit juices and green tea.

Guohua An, Jatinder Kaur Mukker, Hartmut Derendorf, Reginald F Frye

Journal of clinical pharmacology 2016;55(12):1313-31

Full Text

Abstract

Sources of variability in ketoconazole inhibition of human cytochrome P450 3A in vitro.

David J Greenblatt, Karthik Venkatakrishnan, Jerold S Harmatz, Sarah J Parent, Lisa L von Moltke

Xenobiotica; the fate of foreign compounds in biological systems 2011;40(10):713-20

Full Text

Abstract

Cytochrome P450 3A4 inhibition by ketoconazole: tackling the problem of ligand cooperativity using molecular dynamics simulations and free-energy calculations.

Urban Bren, Chris Oostenbrink

Journal of chemical information and modeling 2012;52(6):1573-82

Full Text

Abstract

Effect of botanical immunomodulators on human CYP3A4 inhibition: implications for concurrent use as adjuvants in cancer therapy.

Dada Patil, Manish Gautam, Sunil Gairola, Suresh Jadhav, Bhushan Patwardhan

Integrative cancer therapies 2014;13(2):167-75

Free Full Text

Abstract

Effect of ketoconazole on the pharmacokinetic profile of ambrisentan.

Duncan B Richards, Gennyne A Walker, Arun Mandagere, Mindy H Magee, Linda S Henderson

Journal of clinical pharmacology 2009;49(6):719-24

Full Text

Abstract

4beta-hydroxycholesterol as a marker of CYP3A4 inhibition in vivo - effects of itraconazole in man.

D Lütjohann, M Marinova, B Schneider, J Oldenburg, K von Bergmann, T Bieber, I Björkhem, U Diczfalusy

International journal of clinical pharmacology and therapeutics 2010;47(12):709-15

Full Text

Abstract

Neonatal cytochrome P450 CYP3A7: A comprehensive review of its role in development, disease, and xenobiotic metabolism.

Haixing Li, Jed N Lampe

Archives of biochemistry and biophysics 2020;673():108078

Free Full Text

Abstract

Interaction of grapefruit juice and calcium channel blockers.

Domenic A Sica

American journal of hypertension 2006;19(7):768-73

Full Text

Abstract

Drug-metabolizing enzyme inhibition by ketoconazole does not reduce interindividual variability of CYP3A activity as measured by oral midazolam.

Anne N Nafziger, Joseph S Bertino, Maylee Chen

Drug metabolism and disposition: the biological fate of chemicals 2007;34(12):2079-82

Full Text

Abstract

Pharmacokinetic interaction between the CYP3A4 inhibitor ketoconazole and the hormone drospirenone in combination with ethinylestradiol or estradiol.

Herbert Wiesinger, Matthias Berse, Stefan Klein, Simone Gschwend, Joachim Höchel, Frank S Zollmann, Barbara Schütt

British journal of clinical pharmacology 2016;80(6):1399-410

Free Full Text

Abstract

Abiraterone inhibits 1α,25-dihydroxyvitamin D3 metabolism by CYP3A4 in human liver and intestine in vitro.

Mei Yieng Chin, Hans Adomat, Emma S Tomlinson Guns, Subrata Deb

The Journal of steroid biochemistry and molecular biology 2014;144 Pt A():50-8

Full Text

Abstract

Minimal Physiologically Based Pharmacokinetic and Drug-Drug-Disease Interaction Model of Rivaroxaban and Verapamil in Healthy and Renally Impaired Subjects.

Christopher M Rubino, Mohamed Ismail, Vincent H Lee, Christina R Chow

Journal of clinical pharmacology 2019;58(4):541-548

Full Text

Abstract

Results: 1 – 15 / 163

Filters

Expert Opinion

Text Availability

Publication Types

Publication Year

Results for ""Cytochrome P-450 CYP3A Inhibitors""[mesh_terms]

The role of ketoconazole in current prostate cancer care.

The Mechanism-Based Inactivation of CYP3A4 by Ritonavir: What Mechanism?

Versatile applicability of a grid-based CYP3A4 Template to understand the interacting mechanisms with the small-size ligands; part 3 of CYP3A4 Template study.

Enzyme- and transporter-mediated beverage-drug interactions: An update on fruit juices and green tea.

Sources of variability in ketoconazole inhibition of human cytochrome P450 3A in vitro.

Cytochrome P450 3A4 inhibition by ketoconazole: tackling the problem of ligand cooperativity using molecular dynamics simulations and free-energy calculations.

Effect of botanical immunomodulators on human CYP3A4 inhibition: implications for concurrent use as adjuvants in cancer therapy.

Effect of ketoconazole on the pharmacokinetic profile of ambrisentan.

4beta-hydroxycholesterol as a marker of CYP3A4 inhibition in vivo - effects of itraconazole in man.

Neonatal cytochrome P450 CYP3A7: A comprehensive review of its role in development, disease, and xenobiotic metabolism.

Interaction of grapefruit juice and calcium channel blockers.

Drug-metabolizing enzyme inhibition by ketoconazole does not reduce interindividual variability of CYP3A activity as measured by oral midazolam.

Pharmacokinetic interaction between the CYP3A4 inhibitor ketoconazole and the hormone drospirenone in combination with ethinylestradiol or estradiol.

Abiraterone inhibits 1α,25-dihydroxyvitamin D3 metabolism by CYP3A4 in human liver and intestine in vitro.

Minimal Physiologically Based Pharmacokinetic and Drug-Drug-Disease Interaction Model of Rivaroxaban and Verapamil in Healthy and Renally Impaired Subjects.

Results for
""Cytochrome P-450 CYP3A Inhibitors""[mesh_terms]